Viking Therapeutics, Inc. · NASDAQ:VKTX
Zante Greg sold 21,217 Viking Therapeutics, Inc. shares (Form 4)
Traded Jul 28 to Jul 29, 2026 · Filed Jul 29, 2026
From Jul 28 to Jul 29, 2026, Zante Greg (Chief Financial Officer) sold 21,217 Viking Therapeutics, Inc. shares at US$33.47 for US$710K, leaving 212,204 shares. Filed Jul 29, 2026 (Form 4).
- Sold
- 21,217 shares
- Price
- US$33.47
- Value
- US$710K
- Holding after
- 212,204 shares
- Trading plan
- No
- Role
- Chief Financial Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jul 28, 2026 | Common Stock, par value $0.00001 per share | Award | 31,667 | 233,421 | Direct | |
| Jul 29, 2026 | Common Stock, par value $0.00001 per share | Sale | 21,217 | US$33.47 | 212,204 | Direct |
Source
Related
- Viking Therapeutics, Inc.
- Zante Greg
- Viking Therapeutics, Inc. shareholders
- Form 4 · Kelly-Gemmell Dorothy Elizabeth · Aug 7, 2026
- Form 4 · Lian Brian · Jul 29, 2026
- Form 4 · Mancini Marianna · Jul 29, 2026
- Schedule 13G · Vanguard Capital Management LLC · Apr 30, 2026
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026